Controlled-release phentermine/topiramate in severely obese adults: A randomized controlled trial (EQUIP)

Obesity

Volumn 20, Issue 2, 2012, Pages 330-342

  Allison, David B ^a   Gadde, Kishore M ^b   Garvey, William Timothy ^a   Peterson, Craig A ^c   Schwiers, Michael L ^d   Najarian, Thomas ^c   Tam, Peter Y ^c   Troupin, Barbara ^c   Day, Wesley W ^c  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Menlo Park and VIVUS   (United States)

^d Medpace ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; PHENTERMINE PLUS TOPIRAMATE; PLACEBO; TRIACYLGLYCEROL;

ADULT; AGED; ALOPECIA; ANOREXIA; ANXIETY DISORDER; ARTICLE; ATTENTION DISTURBANCE; BACKACHE; BLOOD PRESSURE MEASUREMENT; BLURRED VISION; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DYSGEUSIA; FATIGUE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPESTHESIA; INFLUENZA; INSOMNIA; LIPID BLOOD LEVEL; MALE; NAUSEA; NEPHROLITHIASIS; OBESITY; OSTEOARTHRITIS; PARESTHESIA; PAROSMIA; POTASSIUM BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UPPER RESPIRATORY TRACT INFECTION; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANTI-OBESITY AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; DELAYED-ACTION PREPARATIONS; DRUG COMBINATIONS; FEMALE; FRUCTOSE; HUMANS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OBESITY, MORBID; PHENTERMINE; WEIGHT LOSS; YOUNG ADULT;

EID: 84856246606     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2011.330     Document Type: Article

References (45)

1. Allison DB, Downey M, Atkinson RL et al. Obesity as a disease: a white paper on evidence and arguments commissioned by the Council of the Obesity Society. Obesity (Silver Spring) 2008;16:1161-1177. (Pubitemid 351770522)
2. Pi-Sunyer FX. A review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity. Clin Ther 1996;18:1006-35; discussion 1005. (Pubitemid 27077108)
3. Franz MJ, VanWormer JJ, Crain AL et al. Weight-loss outcomes: a systematic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc 2007;107:1755-1767. (Pubitemid 47464109)
4. Rothman RB, Baumann MH. Appetite suppressants, cardiac valve disease and combination pharmacotherapy. Am J Ther 2009;16:354-364.
5. Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M; OBES-002 Study Group. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord 2004;28:1399-1410. (Pubitemid 39481843)
6. Bray GA, Hollander P, Klein S et al. A 6-month randomized, placebocontrolled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res 2003;11:722-733. (Pubitemid 41151598)
7. Tonstad S, Tykarski A, Weissgarten J et al. Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension. Am J Cardiol 2005;96:243-251. (Pubitemid 40978583)
8. Richard D, Ferland J, Lalonde J, Samson P, Deshaies Y. Influence of topiramate in the regulation of energy balance. Nutrition 2000;16:961-966.
9. Richard D, Picard F, Lemieux C et al. The effects of topiramate and sex hormones on energy balance of male and female rats. Int J Obes Relat Metab Disord 2002;26:344-353. (Pubitemid 34226159)
10. Picard F, Deshaies Y, Lalonde J, Samson P, Richard D. Topiramate reduces energy and fat gains in lean (Fa/) and obese (fa/fa) Zucker rats. Obes Res 2000;8:656-663.
11. Ben-Menachem E, Axelsen M, Johanson EH, Stagge A, Smith U. Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res 2003;11:556-562. (Pubitemid 41202417)
12. Astrup A, Caterson I, Zelissen P et al. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obes Res 2004;12:1658-1669. (Pubitemid 41132475)
13. Tremblay A, Chaput JP, Bérubé-Parent S et al. The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension. Eur J Clin Pharmacol 2007;63:123-134. (Pubitemid 46147053)
14. Toplak H, Hamann A, Moore R et al. Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Int J Obes (Lond) 2007;31:138-146. (Pubitemid 46006027)
15. Brauer LH, Johanson CE, Schuster CR, Rothman RB, de Wit H. Evaluation of phentermine and fenfluramine, alone and in combination, in normal, healthy volunteers. Neuropsychopharmacology 1996;14:233-241.
16. Magill RA, Waters WF, Bray GA et al. Effects of tyrosine, phentermine, caffeine D-amphetamine, and placebo on cognitive and motor performance deficits during sleep deprivation. Nutr Neurosci 2003;6:237-246. (Pubitemid 36926541)
17. Topamax [product information]. Ortho-McNeil-Janssen Pharmaceuticals, Inc.: Titusville, NJ, 2009.
18. Ryan D, Peterson C, Troupin B et al. Weight loss at 6 months with VI-0521 (PHEN/TPM combination) treatment. Obes Facts 2010;3:146.
19. Brownell KD. The LEARN Program for Weight Management, 10th edn. American Health Publishing Company: Dallas, 2004.
20. Simons-Morton DG, Obarzanek E, Cutler JA. Obesity research-limitations of methods, measurements, and medications. JAMA 2006;295:826-828. (Pubitemid 43244311)
21. Gadde KM, Yonish GM, Foust MS, Tam PY, Najarian T. A 24-week randomized controlled trial of VI-0521, a combination weight loss therapy, in obese adults [abstract]. Obesity 2006;14(Suppl):A17-A18.
22. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. Guidance for Industry: Developing Products for Weight Management. Food and Drug Administration: Rockville, 2007.
23. Lachin JM. Statistical considerations in the intent-to-treat principle. Control Clin Trials 2000;21:167-189. (Pubitemid 30259147)
24. Elobeid MA, Padilla MA, McVie T et al. Missing data in randomized clinical trials for weight loss: scope of the problem, state of the field, and performance of statistical methods. PLoS ONE 2009;4:e6624.
25. Robertson HT, Allison DB. Drugs associated with more suicidal ideations are also associated with more suicide attempts. PLoS ONE 2009;4:e7312.
26. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001;285:2486-2497.
27. Shao J, Jordan DC, Pritchett YL. Baseline observation carry forward: reasoning, properties, and practical issues. J Biopharm Stat 2009;19: 672-684.
28. Mølgaard-Nielsen D, Hviid A. Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA 2011;305:1996-2002.
29. Adipex-P [product information]. Teva Pharmaceuticals USA: Sellersville, PA, 2005.
30. James WP, Caterson ID, Coutinho W et al.; SCOUT Investigators. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010;363:905-917.
31. National Heart, Lung, and Blood Institute. The Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. National Institutes of Health: Bethesda, 1998. NIH Publication No. 98-4083.
32. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010;303:235-241.
33. Smith SR, Weissman NJ, Anderson CM et al.; Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010;363:245-256.
34. Greenway FL, Fujioka K, Plodkowski RA et al.; COR-I Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010;376:595-605.
35. Gadbury GL, Coffey CS, Allison DB. Modern statistical methods for handling missing repeated measurements in obesity trial data: beyond LOCF. Obes Rev 2003;4:175-184. (Pubitemid 36950579)
36. Astrup A, Rössner S. Lessons from obesity management programmes: greater initial weight loss improves long-term maintenance. Obes Rev 2000;1:17-19.
37. Gadde KM, Allison DB, Ryan DH et al. Effects of low-dose, controlledrelease, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:1341-1352.
38. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007;335: 1194-1199. (Pubitemid 350273303)
39. Case CC, Jones PH, Nelson K, O'Brian Smith E, Ballantyne CM. Impact of weight loss on the metabolic syndrome. Diabetes Obes Metab 2002;4: 407-414. (Pubitemid 35345455)
40. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992;16:397-415.
41. UK Prospective Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients, UKPDS group. Metabolism 1990;39:905-912.
42. Buchwald H, Avidor Y, Braunwald E et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004;292:1724-1737. (Pubitemid 39346675)
43. O'Brien PE, Dixon JB, Laurie C et al. Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program: a randomized trial. Ann Intern Med 2006;144:625-633. (Pubitemid 46780646)
44. Rubin DB. Multiple Imputation for Non-Response in Surveys. Wiley Series in Probability and Mathematical Statistics. John Wiley & Sons: New York, 1987.
45. Schafer JL. Analysis of Incomplete Multivariate Data. (Monographs on Statistics and Applied Probability 72). Chapman & Hall/CRC: London, 1997.